Orlando, FL-The relative efficacy of radical prostatectomy andexternal beam radiation therapy for treating clinically localized prostatecancer diagnosed during the PSA era appears to depend on patient risk, accordingto the results of a retrospective study.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.